Cancer Advances, Inc. Announces Abstract and Poster Presentation at ASCO GI – Role of an anti-gastrin vaccine (PAS) in combination with a PD-1 antibody on growth and metastasis of gastric cancer

Jan 19, 2022 | Press Releases, Publication

DURHAM, N.C., Jan. 19, 2022 (GLOBE NEWSWIRE) — Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will host a virtual presentation of its poster at the American Society of Clinical Oncology’s...

Cancer Advances, Inc. Announces Publication, “Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer” in Frontiers in Oncology

Dec 6, 2021 | Press Releases, Publication

DURHAM, N.C., Dec. 06, 2021 (GLOBE NEWSWIRE) — Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in Frontiers in Oncology, section Gastrointestinal Cancers: Gastric...

Vaccination with Polyclonal Antibody Stimulator PAS Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model

Aug 18, 2021 | media-presentation

  About Cancer Advances, Inc. Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by enhancing the adaptive immune system.  The company is led by an experienced...